Ipsen Pharma
8 products tracked · names used in filings: Ipsen Pharma
Upcoming milestones
No upcoming milestones listed.
Recent milestones
Mon 20 Apr 2026🇪🇺 EU approval (EC decision)
Ojemda (tovorafenib) approved in the EU
Marketing authorisation to Ipsen Pharma; Orphan, Conditional, Additional monitoring · source
Thu 26 Feb 2026🇪🇺 CHMP positive opinion
Ojemda (tovorafenib): CHMP positive opinion
Ipsen Pharma; Orphan, Conditional, Additional monitoring · source
Products
| Product | Status | Approved | |
|---|---|---|---|
| 🇪🇺 | Sohonos palovarotene | Refused | |
| 🇪🇺 | Ojemda tovorafenib | Authorised | 2026-04-20 |
| 🇪🇺 | Kayfanda odevixibat | Authorised | 2024-09-19 |
| 🇪🇺 | Iqirvo elafibranor | Authorised | 2024-09-19 |
| 🇪🇺 | Bylvay odevixibat | Authorised | 2021-07-16 |
| 🇪🇺 | Cabometyx cabozantinib | Authorised | 2016-09-09 |
| 🇪🇺 | Cometriq cabozantinib | Authorised | 2014-03-21 |
| 🇪🇺 | NutropinAq somatropin | Authorised | 2001-02-15 |
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.